Biomedical subjects

M A Sortino

Publications and source records attributed to M A Sortino.

At least 55 records · Page 3Linked to original sources

PubMed1991

Measurement of peptide secretion and gene expression in the same cell.

A combined reverse hemolytic plaque-in situ hybridization assay was developed to allow analysis of the relationship between peptide secretion and gene expression within individual cells. We used the pituitary lactotroph as a model system, but this strategy should be widely applicable. It can be used to test hypotheses regarding if and when peptide secretion and gene expression are coupled in any system in which antibodies to the secreted peptide and probes complementary to the mRNA are available. Using the mRNA hybridization signal to identify certain cell types, this method may also be useful in further studies on the biochemical mechanism of peptide secretion. In addition, questions regarding whether a cell known to secrete a given peptide contains other specific mRNAs and the relationship between these mRNAs and the secretion of the peptide can be studied using this strategy. We found striking heterogeneity among lactotrophs in both gene expression and PRL secretion and a lack of correlation of these parameters within individual lactotrophs under every treatment examined. We also present the first direct visualization and quantitation of the percentage of nonsecreting PRL mRNA-containing cells after estradiol treatment and in the presence or absence of the PRL secretagogue, TRH. Finally, we found that in ovariectomized rats, nonsecreting lactotrophs exhibited significantly higher levels of PRL mRNA than lactotrophs that were actively secreting PRL during the assay.

Animals↗

PubMed1991

Maitotoxin increases inositol phosphates in rat anterior pituitary cells.

Maitotoxin is a potent marine poison that mobilizes calcium in most vertebrate cell types and accelerates secretion from anterior pituitary cells. It is not known whether voltage-sensitive calcium channels or other mechanisms initiate the effects of maitotoxin on anterior pituitary cells. Changes in intracellular Ca2+ levels may also be achieved by releasing internal calcium stores via inositol trisphosphate (InsP3). Indeed, maitotoxin rapidly increased inositol phosphate accumulation in a concentration-dependent manner. Calcium channel antagonists such as nifedipine and verapamil did not block this response nor did calcium-mobilizing agents (BAYk8644, A23187) mimic this effect. These data suggest that the mechanism by which maitotoxin acts at the pituitary may include the activation of an enzyme that produces the calcium-mobilizing signal InsP3.

Animals↗

PubMed1990

Inositol hexakisphosphate stimulates 45Ca2+ uptake in anterior pituitary cells in culture.

Inositol hexakisphosphate (InsP6) is thought to act as an intracellular signal molecule in the central nervous system. We report that InsP6 stimulates 45Ca2+ uptake in cultured anterior pituitary cells. This effect is concentration-dependent, is mimicked by inositol-pentakis phosphate (InsP5) but not by inositol-tetrakis phosphate (InsP4), is present after 2 min of incubation, is independent of extracellular Na+ and insensitive to nifedipine and verapamil. These results suggest that InsP6, a putative metabolite of the inositol cycle, may regulate transmembrane mechanism in the pituitary.

Animals↗

PubMed1990

Acute effect of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay.

The effect of basic fibroblast growth factor (bFGF) on acute secretion of PRL by pituitary lactotrophs was examined under basal conditions and after treatment with TRH or dopamine. We used the reverse hemolytic plaque assay (RHPA) to determine the amount of PRL secreted per lactotroph and the percentage of pituitary cells secreting PRL. Young (2- to 3-month-old) female Sprague-Dawley rats were ovariectomized and 1 week later implanted with a Silastic capsule containing 180 micrograms/ml estradiol in sesame oil. Three days later, rats were killed, anterior pituitaries were removed, and cells were enzymatically dispersed and prepared for use in the RHPA. In Exp I, time and dose responses to bFGF were determined using the RHPA. Basic FGF reduced (P less than 0.0001) the mean basal secretion of prolactin per lactotroph. The effect was similar at 30, 60, 120, and 240 min of incubation. The reduction in PRL was greatest at 3.36 x 10(-6) M, while lesser reductions were observed at 1.68 x 10(-6) and 5.60 x 10(-7) M. A dose of 3.36 x 10(-6) M (60 ng/ml) and an incubation time of 60 min were subsequently used in Exp II. In Exp II, we examined the effects of bFGF on TRH stimulation and dopamine inhibition of PRL secretion. PRL secretion was maximally stimulated (P less than 0.01) by 10(-7) M TRH. Basic FGF blocked the TRH-induced increase in PRL secretion. PRL secretion was maximally reduced (P less than 0.001) by 10(-5) M dopamine. Coincubation of bFGF with dopamine reduced (P less than 0.01) the mean plaque area to the same extent as dopamine alone. In each experimental situation changes in mean plaque area reflected a shift in the frequency distribution of the plaque area. Neither bFGF, TRH, dopamine, nor the combined treatments influenced the percentage of pituitary cells secreting PRL compared to basal conditions. We have demonstrated that 1) bFGF reduces the basal secretion of PRL in an acute manner; 2) bFGF blocks the TRH-induced increase in PRL; and 3) bFGF does not potentiate the inhibitory effect of dopamine on PRL secretion and, therefore, may act in part through the same inhibitory pathway as dopamine. We conclude from these data that bFGF, or related factors, could play a role in the regulation of PRL secretion.

Animals↗

PubMed1990

Specific binding sites for inositolhexakisphosphate in brain and anterior pituitary.

[3H]Inositolhexakisphosphate (InsP6) binds to a single population of specific and saturable recognition sites in membranes prepared from cerebral hemispheres, anterior pituitaries, or cultured cerebellar neurons. Binding is temperature and pH dependent, exhibits slow association and dissociation kinetics, and differentiates among various inositolpolyphosphates (InsP6 is much more potent than inositol-1,3,4,5,6-pentakis- and inositol-1,3,4,5-tetrakisphosphate, whereas inositol-1,4,5-trisphosphate is inactive as a displacer). In membranes from cerebral hemispheres, saturation analysis reveals a KD value of 33 +/- 4 nM and a maximal density (Bmax) of 152 +/- 23 pmol/mg of protein. Both affinity and density of [3H]InsP6 binding are lower in membranes from anterior pituitaries. In cultured cerebellar neurons, micromolar concentrations of divalent cations enhance both [3H]InsP6 binding and InsP6-stimulated 45Ca2+ uptake, suggesting that activation of specific receptors may be involved in the stimulation of 45Ca2+ uptake produced by InsP6. These data support the recent view that InsP6, as other inositolpolyphosphates, may act as a signal molecule in excitable cells.

Animals↗

PubMed1989

Involvement of norepinephrine activity in the regulation of alpha 1 adrenergic receptors in the medial preoptic nucleus of estradiol-treated rats.

To establish whether the diurnal decrease in the density of alpha 1 receptors observed in the medial preoptic nucleus (MPN) of estrogen (E2)-treated rats is related to the concomitant diurnal increase in norepinephrine (NE) turnover rates, we quantitated the density of [3H]-Prazosin binding to alpha 1 receptors after blockade of NE turnover with alpha-methyl-paratyrosine (alpha MPT). A series of preliminary studies was performed to rule out an interference of this drug with [3H]-Prazosin binding to alpha 1 adrenergic receptors in vitro and in vivo. Incubation of brain slices with alpha MPT produced a dose-dependent inhibition of [3H]-Prazosin binding to alpha 1 adrenergic receptors with an IC50 of approximately 6 mM. Scatchard analysis demonstrated that alpha MPT exhibited a simple competitive interaction with [3H]-Prazosin binding sites as shown by an increase in the apparent dissociation constant (Kd) of the ligand and no change in the number of alpha 1 receptors (Bmax). In contrast, preincubation of brain slices with alpha MPT and prior in vivo administration of alpha MPT did not affect [3H]-Prazosin binding to alpha 1 adrenergic receptors. Once we established that alpha MPT could be used to suppress NE turnover without interfering with the measurement of alpha 1 receptor densities, we repeatedly injected this drug to ovariectomized (OVX) and E2-implanted rats. The density of alpha 1 adrenergic receptors in MPN was quantitated autoradiographically. Blockade of NE turnover with alpha MPT only partially prevented the reduction in alpha 1 receptor density observed in the E2-treated rats, suggesting that the decrease in the level of [3H]-Prazosin binding sites cannot be completely ascribed to increased NE turnover rates.

Animals↗

PubMed1989

Effect of hyperprolactinemia on luteinizing hormone and prolactin secretion assessed using the reverse hemolytic plaque assay.

Hyperprolactinemia (hyperPRL) frequently suppresses luteinizing hormone (LH) and endogenous rat prolactin (rPRL) secretion under a variety of experimental circumstances. Several lines of evidence suggest that elevated prolactin (PRL) may act at the hypothalamic-pituitary axis to inhibit pituitary hormone secretion. The goal of this study was to determine whether hyperPRL, achieved by administration of ovine PRL (oPRL), influences LH and rPRL secretion as assessed by the reverse hemolytic plaque assay. Young Sprague-Dawley rats were ovariectomized on Day 0 and were treated with oPRL (4 mg/kg body weight, 3 times/day) beginning at 0900 h on Day 4. They were killed at 1000 h on Day 6, anterior pituitaries were collected, and cells were dispersed and prepared for the reverse hemolytic plaque assay. We analyzed mean plaque area by using a computerized image analysis system and determined the percentage of plaque-forming cells by counting the number of plaques compared to the total number of cells. HyperPRL decreases the percentage of LH plaque-forming cells under basal conditions. Although the mean LH plaque area was the same in vehicle-treated and oPRL-treated rats under basal and gonadotropin-releasing hormone-stimulated conditions, hyperPRL altered the frequency distribution of different-sized plaques under basal conditions. It appears that hyperPRL shifts the distribution of different-sized plaques such that there are more small plaques and no plaques of the largest size classes. Basal and thyrotropin-releasing hormone-induced rPRL release from single lactotropes, as measured by mean plaque area and the percentage of plaque-forming cells, is lower in lactotropes from hyperPRL rats than in controls after 1 h, but not 2 h, of incubation.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

PubMed1989

Changing hypothalamopituitary function: its role in aging of the female reproductive system.

Changes in female reproductive function occur relatively early during the life span in many mammalian species. Therefore, this physiological system is an excellent model system in which to study the effects of age on specific endocrine relationships since changes occur prior to the occurrence of multiple pathologies associated with later stages of aging. Data from several laboratories suggest that changes in hypothalamic, pituitary and ovarian function may contribute to age-related deterioration of fertility in females. We will focus our attention on the role of hypothalamic changes in the cascade of events that eventually lead to acyclicity and infertility. Data suggest that changes in the diurnal rhythmicity of catecholaminergic neurotransmitters and their receptors occur during middle age. These changes may regulate the pattern of release of GnRH since alterations in the pulsatile pattern of LH secretion also become detectable at this age. Some age-related changes in hypothalamic and pituitary function are not irreversible or absolutely determined. Instead it appears that the ovarian steroidal milieu modulates the rate of aging of several aspects of hypothalamohypophysial function. In summary, changes in hypothalamic and pituitary function appear to contribute to the aging of the female reproductive system.

Aging↗

PubMed1989

Effects of age and long term ovariectomy on prolactin secretion, as assessed by the reverse hemolytic plaque assay.

PRL secretion from pituitary lactotrophs was assessed using the reverse hemolytic plaque assay in young (2- to 3-month-old), middle-aged (10- to 12-month-old), and middle-aged long term ovariectomized (LT-OVX) rats to investigate whether 1) a change in the percentage of pituitary cells secreting PRL is detectable in middle-aged animals, 2) the amount of PRL secreted per cell changes with age, 3) aging involves a change in responsiveness to TRH and/or dopamine (DA), and 4) LT-OVX can prevent any of these changes. Young and middle-aged rats were OVX for 1 week. LT-OVX rats were OVX at 2-3 months of age and used when they were 10-12 months old. All animals were implanted with Silastic capsules containing estradiol (E2) in sesame oil and killed 3 or 8 days later. Anterior pituitaries were collected, and cells were dispersed and prepared for the reverse hemolytic plaque assay. Three days after E2 was implanted, the percentage of anterior pituitary cells that secrete PRL was higher in middle-aged compared to young rats. LT-OVX prevented this increase; the percentage of cells secreting PRL was significantly lower in LT-OVX than in both young and middle-aged rats. Basal secretion of PRL per cell was not different in young compared to middle-aged rats and was significantly lower in LT-OVX than in either young or middle-aged rats. TRH induced similar increases in plaque size in young and middle-aged rats, but had no effect in LT-OVX rats. DA (10(-7) M) inhibited plaque size only in LT-OVX rats; however, higher concentrations of DA were equally effective in the three experimental groups. Eight days after E2 was implanted, the percentage of cells that secrete PRL increased in LT-OVX rats, but was still significantly lower than that in middle-aged animals. After 8 days of E2 treatment, PRL release was similar in the three experimental groups under basal conditions. In LT-OVX rats TRH produced a small increase in PRL secretion (30-40%); DA suppressed PRL release in a similar manner in the three groups. These data demonstrate that middle-aged rats exhibit an increase in the percentage of cells secreting PRL without a concomitant detectable change in the amount of PRL released by single cells and/or a change in responsiveness to TRH or DA. Long term estrogen deprivation prevents this age-related change, suppresses responsiveness to TRH, and enhances sensitivity to DA.

Aging↗

PubMed1989

Relaxin stimulates prolactin secretion from anterior pituitary cells.

The anterior pituitary has recently been implicated as a relaxin target issue because of the cAMP elevation after relaxin treatment. We attempted to correlate this finding with an endocrine response to relaxin in rats. Anterior pituitary cells were enzymatically dispersed and subjected to the reverse hemolytic plaque assay. PRL secretion was significantly stimulated 1.31-fold by human relaxin at the lowest concentration studied (30 pM) and maximally stimulated 1.65-fold at 0.3 nM relaxin. Antibodies directed against relaxin inhibited this effect, as did the PRL inhibitory hormone, dopamine. In contrast to the response of PRL cells, there was no effect or a slight inhibition of LH release after incubation with relaxin. In conclusion, we propose that one of the pituitary cell types responsive to relaxin in culture is the PRL-secreting mammotroph.

Animals↗

PubMed1988

Gonadotropin-releasing hormone-stimulated phosphoinositide hydrolysis in the anterior pituitary. Modulation by protein kinase C but not by cyclic nucleotides.

Gonadotropin-releasing hormone (GnRH) produces a rapid and concentration-dependent hydrolysis of polyphosphoinositides in rat anterior pituitary cells in culture. Evaluation of the action of the decapeptide by measurement of [3H]-inositol phosphates and of prelabeled phosphoinositides demonstrated an effect on phosphatidylinositol-4,5-bis-phosphate and phosphatidylinositol-4-phosphate earlier than on phosphatidylinositol. The receptor antagonist [D-pGlu1,D-Phe2,D-Trp3,6]-luteinizing hormone-releasing hormone blocked the effect of GnRH on [3H]-inositol phosphate production. Protein kinase C activators attenuated GnRH-induced phosphoinositide hydrolysis, while neither cyclic AMP analogs nor cyclic GMP analogs were effective. These results indicate that phosphoinositide hydrolysis represents an important postreceptor transducing mechanism for GnRH action at the gonadotroph and that protein kinase C (but not cyclic nucleotides) may exert a negative feedback control on GnRH receptor-coupling mechanisms.

Animals↗

PubMed1987

Cholinergic stimulation of inositol phosphate production in cultured anterior pituitary cells.

The effects of acetylcholine and of the muscarinic receptor agonist carbachol on inositol phosphate production were studied in cultured rat anterior pituitary cells. In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects. The increase in the amount of inositol phosphates (primarily inositol trisphosphate and inositol bisphosphate) was very rapid, an effect potently antagonized by the muscarinic receptor antagonist atropine. This agent significantly attenuated the stimulatory effect of carbachol on growth hormone (GH) release. These results indicate that the effects exerted by acetylcholine on anterior pituitary function (i.e. GH release) may be mediated, at least in part, by receptor-activated polyphosphoinositide hydrolysis. In addition, acetylcholine and carbachol's relation with other intracellular pathways and with hormone release is discussed.

Acetylcholine↗

PubMed1986

Protein kinase C enhances growth hormone releasing factor (1-40)-stimulated cyclic AMP levels in anterior pituitary. Actions of somatostatin and pertussis toxin.

The brain peptide human growth hormone releasing factor (1-40) (GRF), which stimulates adenylate cyclase activity in the anterior pituitary, is the predominant hormone signal for pituitary growth hormone (GH) release. Activators of protein kinase C such as teleocidin and 4 beta-phorbol 12-myristate 13-acetate (PMA) double the cyclic AMP accumulation induced by GRF, with no apparent effect on GRF potency; an inactive 4-alpha-PMA has no such action in cultured anterior pituitary cells. This PMA potentiation can be measured as early as 60 s, is maximal by 15 min, and wanes such that by 3-4 h there is no such amplifying effect of PMA. PMA, phorbol 12,13-dibutyrate, and teleocidin ED50 values for potentiating GRF activity are similar to those obtained for direct protein kinase C activation. The major inhibitory peptide somatostatin reduced both GRF- and GRF + PMA-stimulated cyclic AMP accumulation. Pertussis toxin totally blocked this somatostatin action without affecting the degree of maximal GRF potentiation achieved with PMA. Thus, the pertussis toxin target(s) are required for somatostatin inhibition of the cyclic AMP generating system, but may not be involved in the PMA potentiation of GRF-stimulated cyclic AMP accumulation.

Adenylate Cyclase Toxin↗

PubMed1986

Growth hormone releasing factor (GRF) increases free arachidonate levels in the pituitary: a role for lipoxygenase products.

GRF, a specific stimulator of GH release, increased in a concentration- and time-dependent manner pituitary [3H]-arachidonate levels in vitro. This effect was antagonized by 100 nM somatostatin. Exogenous arachidonate also stimulated GH release in vitro. Quinacrine, a phospholipase A2 inhibitor, reduced both basal and GRF-stimulated free arachidonate levels as well as GH release. The cyclooxygenase inhibitor indomethacin was ineffective, while BW755c, which also inhibits the lipoxygenase pathway, produced a further increase in the levels of the fatty acid stimulated by GRF and potently reduced GH release. These results provide additional evidence for the involvement of arachidonate metabolism in the hormone-releasing effect of GRF at the somatotroph.

4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyraz↗

PubMed1985

Estrogen effects on nigral glutamic acid decarboxylase activity: a possible role for catecholestrogen.

Repeated but not single injections of estradiol benzoate significantly reduced nigral glutamic acid decarboxylase (GAD, EC 4.1.1.15). A single injection of the catecholestrogen 2-hydroxyestradiol produced similar results. Tolerance developed to the latter effect, as reflected by the lack of nigral GAD activity changes in rats repeatedly injected with 2-hydroxyestradiol. Repeated injection of the antiestrogen tamoxifen not only failed to antagonize the action of estradiol benzoate but itself reduced nigral GAD activity. Hypophysectomy, which itself decreased nigral GAD activity prevented the lowering effects of either repeated estradiol benzoate administration or single 2-hydroxyestradiol injection on the enzymatic activity.

Animals↗

PubMed1985

Neurotensin stimulates polyphosphoinositide breakdown and prolactin release in anterior pituitary cells in culture.

Biochemical events underlying neurotensin action at the pituitary were investigated in primary culture of anterior pituitary cells prelabeled with [3H]inositol. Incubation with the tridecapeptide produced a dose-dependent increase in the content of total [3H]inositol phosphates. The time-course showed that the effect was rapid and significant within 1 min. Fractionation of [3H]inositol phosphates revealed that inositol triphosphate (IP3) and inositol diphosphate (IP2) increased earlier than inositol monophosphate (IP1). Structure/activity correlation studies demonstrated the specificity of neurotensin effect, showing that acetylneurotensin(8-13) displayed an action similar to the natural peptide, while neurotensin(1-6) hexapeptide did not exhibit any effect. The neurotensin analog [D-Trp11]-neurotensin antagonized in a concentration-dependent manner the effect of neurotensin both on prolactin release and on [3H]inositol phosphate production. The loss of prelabeled phosphoinositides was also investigated. Phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) and phosphatidylinositol-4-phosphate (PtdIns-4-P) decreased significantly within 15 s, while a slight decline in phosphatidylinositol (PtdIns) level appeared only 1 min after neurotensin addition. These results suggest that neurotensin action at the pituitary is mediated by the early hydrolysis of polyphosphoinositides, leading to the production of 1,2-diacylglycerol and inositol phosphates which may initiate intracellular processes responsible for hormonal release.

Animals↗

PubMed1985

Involvement of arachidonate metabolism in neurotensin-induced prolactin release in vitro.

Neurotensin increased in a concentration-dependent manner the level of hypophyseal [3H]arachidonic acid in vitro as well as prolactin release from hemipituitary glands. The effect of 1 microM neurotensin on arachidonate release was already present at 2.5 min, maximal at 5, and disappeared after a 10-min incubation. Neurotensin analogues produced an enhancement of hypophyseal arachidonate similar to their relative potencies in other cellular systems, whereas other peptides (somatostatin and vasoactive intestinal peptide) were devoid of any effect on the concentration of the fatty acid in the pituitary. Seventy micromoles RHC 80267, a rather selective inhibitor of diacylglycerol lipase, completely prevented the neurotensin-stimulated prolactin release and decreased arachidonate release both in basal or in neurotensin-induced conditions. Similar results were obtained with 50 microM quinacrine, a phospholipase A2 inhibitor. To clarify whether arachidonate released by neurotensin requires a further metabolism through specific pathways to stimulate prolactin release, we used indomethacin and BW 755c, two blockers of cyclooxygenase and lipoxygenase pathways. Thirty micromoles indomethacin, a dose active to inhibit cyclooxygenase, did not affect unesterified arachidonate levels either in basal or in neurotensin-induced conditions; moreover, the drug did not modify basal prolactin release but slightly potentiated the stimulatory effect of neurotensin on the release of the hormone. On the other hand, 250 microM BW 755c, an inhibitor of both cyclooxygenase and lipoxygenase pathways, significantly inhibited both basal and neurotensin-stimulated prolactin release and further potentiated the increase of the fatty acid concentrations produced by 1 microM neurotensin.(ABSTRACT TRUNCATED AT 250 WORDS)

4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyraz↗

PubMed1985

Phospholipid metabolism and prolactin secretion in vitro.

The possible mechanisms by which phospholipid metabolism may be involved in the biochemical events underlying pituitary hormone secretion in basal and stimulated conditions were examined. Particular emphasis was given to the role of changes in the turnover of specific membrane phospholipids, the polyphosphoinositides, in the stimulatory effect of TRH and neurotensin on prolactin release in vitro. Finally, some comments on the involvement of arachidonate and/or its metabolites in the mechanisms of release of the hormone have been reported. In this respect, the possibility that a specific diacylglycerol lipase may represent a link between the 'phosphatidylinositol effect' and the production of arachidonate from mammotroph membranal phospholipids was examined using the rather selective inhibitor of diacylglycerol lipase RHC80267.

Animals↗